A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas

被引：2

作者：

Song, Yuqin ^{[1
]}

Li, Zengjun ^{[2
]}

Wu, Huijing ^{[3
]}

Jin, Jie ^{[4
]}

Zhou, Hui ^{[5
]}

Zhou, Keshu ^{[6
]}

Zhang, Liling ^{[7
]}

Peng, Zhigang ^{[8
]}

Zhang, Zhiye ^{[9
]}

Cen, Hong ^{[10
]}

Jia, Youchao ^{[11
]}

Shuang, Yuerong ^{[12
]}

Li, Zhiming ^{[13
]}

Yang, Haiyan ^{[14
]}

Zou, Liqun ^{[15
]}

Li, Zhifeng ^{[16
,17
]}

Zhang, Zhihui ^{[18
]}

Li, Junmin ^{[19
]}

Cao, Junning ^{[20
]}

Qiu, Lugui ^{[21
]}

Wu, Shaojie ^{[22
]}

Gong, Tiejun ^{[23
]}

Xu, Xiaohong ^{[24
]}

Wang, Zhen ^{[25
]}

Zhu, Jun ^{[26
]}

机构：

[1] Peking Univ, Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[3] Hubei Canc Hosp, Wuhan, Peoples R China

[4] Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[5] Hunan Canc Hosp, Changsha, Peoples R China

[6] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[7] Huazhong Univ Sci & Technol, Canc Ctr, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[8] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Oncol, Naning, Peoples R China

[9] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Oncol, Luoyang, Peoples R China

[10] Guangxi Med Univ, Affiliated Tumor Hosp, Dept Med Oncol, Nanning, Peoples R China

[11] Hebei Univ, Dept Med Oncol, Affiliated Hosp, Baoding, Peoples R China

[12] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[13] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China

[14] Zhejiang Canc Hosp, Hangzhou, Peoples R China

[15] Sichuan Univ, Dept Med Oncol, West China Sch Med, West China Hosp, Chengdu, Peoples R China

[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China

[18] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China

[19] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China

[20] Fudan Univ, Shanghai Canc Ctr, Dept Lymphoma, Shanghai, Peoples R China

[21] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol & Blood Dis H, Tianjin, Peoples R China

[22] Southern Med Univ, Zhujiang Hosp, Dept Hematol, Guangzhou, Peoples R China

[23] Harbin First Hosp, Inst Hematol & Oncol, Harbin, Peoples R China

[24] Nantong Univ, Dept Hematol & Lymphoma, Canc Hosp, Nantong, Peoples R China

[25] Linyi Canc Hosp, Linyi, Shandong, Peoples R China

[26] Peking Univ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Canc Hosp & Inst,Minist Educ, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180137

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas
Strati, Paolo
Oki, Yasuhiro
Fayad, Luis E.
Nastoupil, Loretta
Fowler, Nathan H.
Hagemeister, F. B.
Kwak, Larry W.
Lee, Hun Ju
Wang, Michael
Westin, Jason R.
Ruben, Charnelle
Wesson, Emily
Fanale, Michelle A.
BLOOD, 2017, 130
[22] A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
Strati, Paolo
Nastoupil, Loretta J.
Davis, Richard E.
Fayad, Luis E.
Fowler, Nathan
Hagemeister, Fredrick B.
Kwak, Larry
Oki, Yasuhiro
Wang, Michael
Westin, Jason
Ruben, Charnelle E.
Wesson, Emily T.
Piekarz, Richard
Fanale, Michelle A.
Lee, Hun Ju
HAEMATOLOGICA, 2020, 105 (01) : E26 - E28
[23] Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
Zinzani, Pier Luigi
Bonthapally, Vijayveer
Huebner, Dirk
Lutes, Richard
Chi, Andy
Pileri, Stefano
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 99 : 214 - 227
[24] A Global Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With EBV-Positive (EBV plus ) Relapsed/Refractory Peripheral T Cell Lymphomas (NAVAL-
Nair, Ranjit
Chang, Hung
Greenwell, Irl Brian
Hsiao, Hui-Hua
Ayer, Swaminathan
Zinzani, Luigi
Strickland, Donald
Gonzalez-Barca, Eva
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S527 - S527
[25] Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas
Kim, Seok Jin
Lee, Myung-Won
Lim, Sung-Nam
Kang, Ka-Won
Yoon, Sang Eun
Lee, Yoo Jin
Kang, Hye Jin
Lee, Ho Sup
Kim, Hyo Jung
Koo, Hong Hoe
Shin, Ho-Jin
Eom, Hyeon-Seok
Won, Jong-Ho
Kim, Won Seog
BLOOD, 2023, 142
[26] A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas
Boonstra, Philip S.
Polk, Avery
Brown, Noah
Hristov, Alexandra C.
Bailey, Nathanael G.
Kaminski, Mark S.
Phillips, Tycel
Devata, Sumana
Mayer, Tera
Wilcox, Ryan A.
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (12) : 1287 - 1294
[27] Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era
Boussi, Leora S.
Koh, Min Jung
Han, Xinyi
Peng, Luke
Koh, Min Ji
Eche, Ijeoma
Ford, Josie Germain
Singh, Shambhavi
Miranda, Eliana
Chiattone, Carlos S.
Van der Weyden, Carrie
Prince, Henry Miles
Foss, Francine M.
Yoon, Sang Eun
Kim, Won-Seog
Panchoo, Girisha
Verburgh, Estelle
Alturas, Jackielyn Cuenca
Al-mansour, Mubarak
Manni, Martina
Federico, Massimo
Cabrera, Maria Elena
Casadei, Beatrice
Zinzani, Pier Luigi
Yoshida, Noriaki
Okatani, Takeshi
Merrill, Mwanasha H.
Jacobsen, Eric D.
O'Connor, Owen A.
Marchi, Enrica
Jain, Salvia
BLOOD, 2022, 140 : 10976 - 10978
[28] Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Horwitz, Steven M.
Nirmal, Ajit J.
Rahman, Jahan
Xu, Ran
Drill, Esther
Galasso, Natasha
Ganesan, Nivetha
Davey, Theresa
Hancock, Helen
Perez, Leslie
Maccaro, Catherine
Bahgat, Alexandra
Marzouk, Evan
Cathcart, Elizabeth
Moskowitz, Alison
Noy, Ariela
Kumar, Anita
Jacobsen, Eric
Fisher, David C.
Mehta-Shah, Neha
Kim, Youn H.
Khodadoust, Michael
Kotlov, Nikita
Nikitina, Anastasia
Kudryashova, Olga
Zubareva, Valeria
Zornikova, Ksenia
Shin, Nara
Sorokina, Maria
Degryse, Sandrine
Postovalova, Ekaterina
Bagaev, Aleksander
Hosszu, Kinga
Mcavoy, Devin
Boelens, Jaap J.
Wu, Wenchao
Ciantra, Zoe
Appelt, Jackson W.
Trevisani, Christopher
Amaka, Sam
Weinstock, David M.
Vardhana, Santosha A.
NATURE MEDICINE, 2024, : 3778 - 3778
[29] Combining the mTOR Inhibitor Everolimus and Gemcitabine in Relapsed/Refractory Peripheral T-Cell Lymphomas
Huang, Ling
Jiang, Xinmiao
Li, Wenyu
Guo, Hanguo
Wei, Xiaojuan
Liu, Sichu
Chen, Feili
Liang, Zhanli
BLOOD, 2020, 136
[30] Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Multicenter, Single-Arm, Open-Label, Phase 2 Clinical Trial
Huang, Hui-qiang
Huang, Yunhong
Yan, Gao
Yang, Haiyan
Zhang, Qingyuan
Yang, Runxiang
Zhou, Min
Li, Yufu
Li, Yan
Liu, Lihong
Zhou, Hui
Jing, Hongmei
Peng, Zhigang
Yu, Ding
Zhang, Rong Yan
Xu, Bing
Zhang, Xiaohong
Qi, Junyuan
Ma, Liping
Chen, Shan
Xue, Jianfei
BLOOD, 2019, 134

← 1 2 3 4 5 →